Cartesian Therapeutics Inc. (RNAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has a cash flow conversion efficiency ratio of 0.435x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.60 Million) by net assets ($-35.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cartesian Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Cartesian Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read RNAC total liabilities for a breakdown of total debt and financial obligations.
Cartesian Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shuttle Inc
TW:2405
|
0.006x |
|
Laser Tek Taiwan Co Ltd
TWO:6207
|
0.037x |
|
Superior Uniform Group Inc
NASDAQ:SGC
|
-0.009x |
|
MotorK Ltd
AS:MTRK
|
-0.020x |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
0.023x |
|
Jean Co Ltd
TW:2442
|
0.122x |
|
Haesung Industrial Co. Ltd
KQ:034810
|
0.020x |
|
SK D&D Co Ltd
KO:210980
|
-0.133x |
Annual Cash Flow Conversion Efficiency for Cartesian Therapeutics Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Cartesian Therapeutics Inc. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see RNAC market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.80 Million | $-23.67 Million | 3.480x | +2894.54% |
| 2023-12-31 | $-440.18 Million | $-51.16 Million | 0.116x | +134.48% |
| 2022-12-31 | $93.83 Million | $-31.63 Million | -0.337x | +87.43% |
| 2021-12-31 | $22.52 Million | $-60.38 Million | -2.681x | -38.40% |
| 2020-12-31 | $-18.01 Million | $34.88 Million | -1.937x | +68.37% |
| 2019-12-31 | $8.40 Million | $-51.44 Million | -6.125x | -156.10% |
| 2018-12-31 | $-5.42 Million | $-59.16 Million | 10.919x | +1187.25% |
| 2017-12-31 | $51.81 Million | $-52.04 Million | -1.004x | -180.41% |
| 2016-12-31 | $54.96 Million | $-19.68 Million | -0.358x | -285.74% |
| 2015-12-31 | $-116.49 Million | $-22.46 Million | 0.193x | +33.39% |
| 2014-12-31 | $-87.75 Million | $-12.69 Million | 0.145x | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic l… Read more